Nautilus Biotechnology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nautilus Biotechnology generated cash of -$51,711,000, which is less than the previous year. Cash used in financing activities reached the amount of $368,000 last year. Net change in cash is therefore -$95,078,000.
Cash Flow
| 2018 | -238.29M | 1.19M | 145.18B |
|---|---|---|---|
| 2019 | -9.66M | 4.05M | 36K |
| 2020 | -13.99M | -25.27M | 75.89M |
| 2021 | -39.24M | -138.96M | 327.44M |
| 2022 | -45.80M | -25.74M | 562K |
| 2023 | -51.71M | -43.73M | 368K |
NAUT Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 115.47M | 186.46M | 37.21M | 595K | 1.19B | 0 |
Operating activities | ||||||
Net income | -63.67M | -57.92M | -50.31M | -15.61M | -9.61M | 626.6M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 5.70M | 3.41M | 2.84M | 2.34M | 548K | 0 |
Stock-based compensation expense | 12.13M | 10.38M | 7.93M | 369K | 110K | 0 |
| Deferred income tax benefit | 12.13M | 10.38M | 7.93M | 369K | 110K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 393K | -561K | 1.26M | 123K | 107.24K | 0 |
Cash generated by operating activities | -51.71M | -45.80M | -39.24M | -13.99M | -9.66M | -238.29M |
Investing activities | ||||||
Purchases Of Investments | -112.89M | -186.59M | -221.79M | -68.35M | 0 | 0 |
Investments In Property Plant And Equipment | -2.44M | -2.32M | -2.26M | -921K | -926K | 0 |
Acquisitions Net | 0 | -163.17M | 136.69K | 24.35K | 0 | 0 |
Cash generated by investing activities | -43.73M | -25.74M | -138.96M | -25.27M | 4.05M | 1.19M |
Financing activities | ||||||
Common Stock Issued | 368K | 562K | -7.96M | 75.89M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 264K | 232K | 0 | 0 | -874.32K | -1.19M |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 368K | 562K | 327.44M | 75.89M | 36K | 145.18B |
Net Change In Cash | -95.07M | -70.98M | 149.24M | 36.62M | -1.19B | 1.19M |
Cash at end of period | 20.39M | 115.47M | 186.46M | 37.21M | 595K | 1.19M |
| Data source | Data source | Data source | Data source | Data source | Data source |